Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
暂无分享,去创建一个
Neha Korde | Venkata Yellapantula | Elli Papaemmanuil | E. Papaemmanuil | I. Maric | O. Landgren | N. Korde | S. Mailankody | M. Hultcrantz | Irina Maric | Sham Mailankody | D. Kazandjian | Dickran Kazandjian | Ola Landgren | Malin Hultcrantz | Theresia Akhlaghi | M. Kwok | Elizabeth Hill | Evan H. Rustad | Alex Dew | Mary Kwok | Alexander Dew | T. Akhlaghi | V. Yellapantula | Elizabeth M. Hill
[1] W. Wilson,et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. , 2017, Blood advances.
[2] S. Rajkumar,et al. Elucidating disparities across racial and ethnic groups in multiple myeloma patients , 2012, International Journal of Hematology.
[3] M. Grever,et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. , 2015, The New England journal of medicine.
[4] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[5] R. Bataille,et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.
[6] J. Cerhan,et al. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry , 2018, Blood Cancer Journal.
[7] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Brown,et al. Molecularly targeted therapies for p53-mutant cancers , 2017, Cellular and Molecular Life Sciences.
[9] H. Goldschmidt,et al. Targeting the BRAF V600E mutation in multiple myeloma. , 2013, Cancer discovery.
[10] H. Einsele,et al. First targeted therapy in multiple myeloma. , 2017, Blood.
[11] R. Fonseca,et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. , 2002, Blood.
[12] N. Munshi,et al. Genomics of Multiple Myeloma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] K. McGlynn,et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. , 2010, Blood.
[14] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[15] H. Goldschmidt,et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. , 2018, Blood.
[16] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[17] C. Bastard,et al. Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.
[18] P. Secchiero,et al. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer , 2017, Journal of Hematology & Oncology.
[19] G. Parmigiani,et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.
[20] D. Kazandjian. Multiple myeloma epidemiology and survival: A unique malignancy. , 2016, Seminars in oncology.
[21] D. Landau,et al. Genomic complexity of multiple myeloma and its clinical implications , 2017, Nature Reviews Clinical Oncology.
[22] F. Schmidt. Meta-Analysis , 2008 .
[23] A. Nagler,et al. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable? , 2016, Genes, chromosomes & cancer.
[24] Shaji K. Kumar,et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. , 2017, Blood advances.
[25] G. Dotto,et al. Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin? , 2017, Trends in cancer.
[26] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[27] Gordon Cook,et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] O. Landgren,et al. Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. , 2014, Clinical advances in hematology & oncology : H&O.
[29] Winnie S. Liang,et al. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases , 2017, PLoS genetics.
[30] R. Fonseca,et al. Clinical significance of TP53 mutation in myeloma , 2007, Leukemia.
[31] G. Morgan,et al. The genetic architecture of multiple myeloma , 2012, Nature Reviews Cancer.
[32] X. Gou,et al. Prognostic value of 1p deletion for multiple myeloma: a meta‐analysis , 2014, International journal of laboratory hematology.
[33] J. Carpten,et al. Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression , 2014 .
[34] G. Morgan,et al. Evolutionary biology of high-risk multiple myeloma , 2017, Nature Reviews Cancer.
[35] J. Blay,et al. Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study , 2015 .
[36] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[37] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[38] D. Dingli,et al. Natural history of t(11;14) multiple myeloma , 2017, Leukemia.
[39] J. Sawyer. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. , 2011, Cancer genetics.
[40] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.